Skip to main content
SpringerLink
Log in

Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Degradation of basement membranes and extracellular matrix is an essential step in cancer invasion and metastasis. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play key roles in this step. The present study was conducted to investigate the levels of MMP-3 and TIMP-1 in serum of patients with malignant melanoma and the relationship to tumor progression and known prognostic parameters. Seventy patients with cutaneous malignant melanoma were investigated. Serum samples were obtained on first admission before any adjuvant and metastatic treatment was given or follow-up of patients. Serum TIMP-1 and MMP-3 levels were determined by the solid-phase sandwich ELISA (Oncogene Science Inc.) method. The elevation of serum MMP-3 and TIMP-1 levels between the patients with malignant melanoma and healthy controls were not significantly different (p>0.05). The serum levels of MMP-3 were significantly different in males and females (p=0.001) and serum TIMP levels were influenced by age (p=0.047). Except for the ulceration status of the tumor, serum levels of MMP-3 and TIMP-1 were not related to the known prognostic factors such as tumor histology, localization, stage of the disease, Breslow thickness, Clark invasion, mitosis, TIL, and regression of tumor (p>0.05). In patients with ulceration positive, the serum levels of MMP-3 were higher (p=0.04) and TIMP-1 were lower (p=0.008) than those in patients without ulceration. No significant relationship was found between serum levels of MMP-3 and TIMP-1. In conclusion, these results suggest that neither of the serum levels of MMP-3 and TIMP-1 could be a good indicator of invasion and metastasis nor can be recommended as a tumor marker in the management of melanoma patients owing to lack of sensitivity and specificity. However, much research still continues in this field and exciting new knowledge will ultimately emerge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Natl Cancer Inst 1997;89:1260–1270.

    Article  CAS  Google Scholar 

  2. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 1998;12:1343–1348.

    PubMed  CAS  Google Scholar 

  3. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823–4830.

    PubMed  CAS  Google Scholar 

  4. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157–166.

    Article  PubMed  CAS  Google Scholar 

  5. Hofmann UB, Westphal JR, van Muijan GNP, Ruiter D. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337–344.

    Article  PubMed  CAS  Google Scholar 

  6. Kahari VM, Saarialho-Kere U. Matrix proteinases and their inhibitors in tumor growth and invasion. Ann Med 1999;31:34–45.

    PubMed  CAS  Google Scholar 

  7. Gojhi K, et al. Elevation of serum levels of matrix metalloproteinase-2 and-3 as a new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379–2387.

    Article  Google Scholar 

  8. Liokumovich P, et al. Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis. J Clin Pathol 1999;52:198–202.

    Article  PubMed  CAS  Google Scholar 

  9. Michael M, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802–1808.

    PubMed  CAS  Google Scholar 

  10. El-Shabrawi Y, Ardjomand N, Radner H, Ardjomand N. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol 2001;194:201–206.

    Article  PubMed  CAS  Google Scholar 

  11. Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growth stimulatory activity: a concentration and cell type-specific response in the presence of insulin. Exp Cell Res 1996;224:110–115.

    Article  PubMed  CAS  Google Scholar 

  12. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111–122.

    PubMed  CAS  Google Scholar 

  13. Walker RA, Woolley DE. Immunolocalisation studies of matrix metalloproteinases-1,-2, and -3 in human melanoma. Virchows Arch 1999;435:574–579.

    Article  PubMed  CAS  Google Scholar 

  14. Hofmann UB, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999;81:774–782.

    Article  PubMed  CAS  Google Scholar 

  15. Asai M, et al. Differential regulation of MMP-9 and TIMP-2 expression in malignant melanoma developed in metallothionein/RET transgenic mice. Jpn J Cancer Res 1999;90:86–92.

    PubMed  CAS  Google Scholar 

  16. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Matrix metalloproteinase expression in malignant melanoma: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 2001;15:57–64.

    PubMed  CAS  Google Scholar 

  17. de Lorenzo MS, et al. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 2003;17:45–50.

    PubMed  Google Scholar 

  18. Hoashi T, Kadono T, Kikuchi E, Etoh T, Tamaki T. Differential growth regulation in human melanoma cell lines by TIMP-1 and TIMP-2. Biochem Biophys Res Commun 2001;288:371–379.

    Article  PubMed  CAS  Google Scholar 

  19. Airola K, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733–743.

    Article  PubMed  CAS  Google Scholar 

  20. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432–438.

    Article  PubMed  CAS  Google Scholar 

  21. Saida T. Recent advances in melanoma. J Dermatol Sci 2001;26:1–13.

    Article  PubMed  CAS  Google Scholar 

  22. Meric JB, Beaudeux JL, Mouawad R, Cajfinger F, Khayat D, Rixe O. Relevance of matrix metalloproteinase (MMP) plasma levels in malignant melanoma (MMM). Proc Am Soc Clin Oncol 2003;22:721, abstract 2899.

    Google Scholar 

  23. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Kim DK, Das Gupta TK. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastasis. Surgery 1995;118:669–673.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkoloji Enstitusu, Capa, Istanbul Universitesi, 34390, Istanbul, Turkey

    Faruk Tas, Derya Duranyildiz, Hilal Oguz, Rian Disci, Sidika Kurul, Vildan Yasasever & Erkan Topuz

Authors
  1. Faruk Tas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derya Duranyildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hilal Oguz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rian Disci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sidika Kurul
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vildan Yasasever
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erkan Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faruk Tas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tas, F., Duranyildiz, D., Oguz, H. et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol 22, 39–44 (2005). https://doi.org/10.1385/MO:22:1:039

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:22:1:039

Key Words

Search

Navigation